Objectives-To evaluate the efficacy of a picture archiving and communication system (PACS)-based ultrasound (US) quantification technique for diagnosis of hepatic steatosis in a pediatric population.
H epatic steatosis is a term applied to a spectrum of diseases characterized by triglyceride accumulation within the cytoplasm of liver cells. 1 The most common acquired condition associated with childhood hepatic steatosis is nonalcoholic fatty liver disease (NAFLD), with an estimated prevalence of 9.6%. 1 Nonalcoholic fatty liver disease may be either simple steatosis or nonalcoholic steatohepatitis (NASH) and has the potential to progress to cirrhosis. 1 Hepatic steatosis may also be seen in other conditions, including viral hepatitis, protein energy malnutrition, drug toxicity, Wilson disease, and cystic fibrosis. 1 Due to the increasing incidence of childhood obesity, more children are at risk for developing hepatic steatosis and its associated metabolic comorbidities such as diabetes mellitus and cardiovascular diseases. 2 Although histopathologic analysis is considered the reference standard for the diagnosis of hepatic steatosis, noninvasive diagnostic alternatives to liver biopsy are preferred to avoid risks of liver biopsy in children. 1 Most studies in the literature focus on the imaging diagnosis of hepatic steatosis in adults, but there is a need for validated studies in children with biopsy-proven liver disease regarding imaging as an initial screening tool or followup to monitor treatment. 1 Ultrasound (US) is generally favored as the initial imaging modality for the diagnosis of suspected liver diseases in both adults and children. It is readily available, free of ionizing radiation, and easy to apply in pediatric patients because of their small size and lack of intra-abdominal fat. 3 In current clinical practice, assessment of liver echogenicity is subjective, based on visual inspection. 4 To overcome the variability of subjective US assessments, quantitative measurement of the grayscale echo intensity of tissues in multiple anatomic locations, including breast, thyroid, ascitic fluid, and liver, has been promoted by several investigators. [5] [6] [7] [8] [9] [10] [11] [12] [13] Among these, the hepatorenal ratio has been used for quantification of liver parenchyma using kidneys as reference tissue. [9] [10] [11] [12] Most of these investigations of the liver grayscale echo intensity, however, have been performed with special software and computer systems, requiring cumbersome transfer of images and manual measurements. To address this obstacle, Shiralkar et al 10 developed a more practical alternative using a readily available picture archiving and communication system (PACS) to measure the grayscale US echo intensity. To our knowledge there are only a few studies, such as those by Lee et al 13 and Shiralkar et al, 10 that used a PACS tool for measurement of the liver grayscale echo intensity as an adjunct to subjective US imaging to help predict liver diseases. In particular, Shiralkar et al 10 initiated the use of the hepatorenal ratio method using PACS. Moreover, these PACS studies were performed in adults, with little data available in children. 10, 13 The aim of this study, therefore, was to evaluate the efficacy of a PACS-based US quantification technique for diagnosis of hepatic steatosis compared to diffuse nonsteatotic liver disease and normal livers in a pediatric population.
Materials and Methods
This retrospective study was approved by Institutional Review Board of our medical center, and written informed consent was waived. Patient records were anonymized and deidentified before analysis.
Study Population
From February 2004 through October 2016, a total of 60 consecutive pediatric patients aged 18 years and younger who were referred to the radiology department for the purpose of US-guided liver biopsy were identified in our database. An additional inclusion requirement was the presence of diagnostic abdominal US images in our PACS within the 3 months before biopsy. Exclusion criteria were the presence of renal disease, use of medications with the potential to alter liver or kidney echogenicity, the presence of large amount of ascites, and age younger than 1 year (because of the physiologic hyperechogenicity of renal parenchyma). From this initial total count of 60 patients, 11 who underwent tissue sampling from hepatic mass lesions (5 hepatoblastoma, 2 focal nodular hyperplasia, 2 metastatic neuroblastoma, 1 poorly differentiated carcinoma, and 1 triphasic Wilms tumor) but not from liver parenchyma were excluded. Thus, 49 patients ultimately constituted the study population.
Patients were separated into 3 groups as follows: control group (n 5 3) with no abnormal histologic results; hepatic steatosis group (n 5 17) with the presence of steatosis involving greater than 5% of hepatic parenchyma; and nonsteatotic liver disease group (n 5 19) with steatosis involving less than 5% of hepatic parenchyma, histologic evidence of portal or lobular inflammation, fibrosis, or both, or positive hepatitis B or C serologic markers.
Ultrasound Examinations
All patients underwent diagnostic focused abdominal US examinations using a variety of scanners (Acuson Sequoia 512 and XP128; Siemens Medical Solutions, Mountain View, CA) equipped with broadband curved array transducers (4) (5) (6) (7) (8) . The right upper abdominal quadrant was scanned by a subcostal approach with the patient supine. The depth of the display was 8 to 15 cm. All US examinations were performed by experienced pediatric sonographers. Both still and cine US images were stored in the Digital Imaging and Communications in Medicine format. All digital data were transferred to our PACS server (Inteleviewer version 4.11.1; Intelerad Medical Systems, Montreal, Quebec, Canada).
Tissue Diagnosis
Patients were referred for tissue diagnosis by either pediatric gastroenterologists or general pediatricians on the basis of high liver function test results (total bilirubin, aspartate aminotransferase, alanine aminotransferase, g-glutamyl transferase, alkaline phosphatase, albumin), positive chronic hepatitis markers, or clinical conditions associated with parenchymal liver disease. All of the control patients who underwent core biopsy had persistent elevation of liver function test results, and 1 had associated gallstones.
Forty-six of the patients, including all of the patients with hepatic steatosis and nonsteatotic liver disease and 10 of the controls, were evaluated by percutaneous core biopsy. The core biopsy procedures were performed in the radiology department by board-certified interventional or pediatric radiologists by percutaneous intercostal techniques using 18-or 20-gauge core needles with US guidance under local or general anesthesia. Two or 3 core needle liver biopsy samples were obtained from the right hepatic lobe of each patient. The 3 other control patients were evaluated by open surgical biopsy. One underwent wedge resection for focal nodular hyperplasia, and normal liver tissue was sampled at the same time; the focal nodular hyperplasia lesion was far from the region of interest (ROI) that we used to measure the liver echo intensity, eliminating the potential to influence the US measurements. Another control patient underwent liver biopsy during gastric bypass surgery for morbid obesity. The third patient underwent cholecystectomy, and a sample from liver tissue was taken at the time of surgery.
The pathologic diagnosis was obtained from the patient record database. The presence of liver fibrosis was evaluated according to the METAVIR score. 14 Fibrosis was classified as follows: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis and few septa; F3, numerous septa without cirrhosis; and F4, Cirrhosis.
14 Hepatic steatosis was defined as large triglyceride droplet accumulation within liver cells and quantitatively graded as normal, if comprising less than 5% of the specimen, mild if 5% to 29%, moderate if 30% to 59%, and severe, if greater than 59%. 15 Patients with hepatic steatosis were defined as having NAFLD on the basis of the previous descriptions in the pediatric literature, which included persistent elevation of serum alanine aminotransferase (>35 U/L) and subjectively echogenic liver detected by US, along with exclusion of the following conditions causing chronic hepatitis: hepatitis B, hepatitis C, a 1 -antitrypsin deficiency, autoimmune hepatitis, Wilson disease, drug toxicity, total parenteral nutrition, and alcohol intake. 16 Patients with hepatic steatosis from causes apart from NAFLD were also noted.
Image Analysis
At a PACS workstation, the liver and kidneys were briefly evaluated for echogenic characteristics, the presence of any mass lesion or any vascular abnormalities, and the presence of ascites. Then, a radiologist with more than 10 years of experience, who was blinded to the pathologic results, performed quantitative grayscale measurements from the still images using the method described by Shiralkar et al. 10 A circular ROI of 0.5 to 1.5 cm 2 was manually drawn on the PACS liver image located in the central focusing area at a variable depth from liver surface, which was dependent on patient age and size. Areas containing vessels, bile ducts, parenchymal calcifications, or US artifacts were avoided. In the graphic program integrated into the PACS, the mean grayscale echo intensity values from the ROI were automatically displayed on screen and expressed in pixels ranging from 0 (black) to 255 (white; Figure 1 ). The standard deviation (SD) was also provided as a measure of variation of the grayscale echo intensity values.
To account for individual and B-mode parameter variabilities (gain, depth range, and dynamic range), quantitative grayscale echo intensity measurements were also obtained from the kidneys on the identical PACS image frame. For the kidneys, an ROI of 0.3 to 0.6 cmmeasurements were repeated 3 times and the averages recorded.
To provide a standard reference for liver grayscale echo intensity values, the hepatorenal ratio for each pair of liver and kidney grayscale echo intensity PACS measurements was calculated by dividing the mean hepatic echo intensity value by the mean renal echo intensity value. The ratio of the liver to kidney echo intensity rather than the absolute value of the liver echo intensity was used to eliminate influences from disparities in gain and time-gain compensation settings, thereby allowing for comparison between patients. As a measure of the coefficient of variation of the liver echo intensity, the heterogeneity index was calculated by dividing the mean liver SD value by the mean liver echo intensity value for each liver PACS ROI measurement. The hepatorenal ratio and heterogeneity index values were correlated with pathologic results.
To validate the PACS measurement tool, a random sample of 20 US images (both normal and diseased) from our patient population was selected. Images were transferred from the PACS to ImageJ software (National Institutes of Health, Bethesda, MD), an application that has been widely used in past studies of US grayscale quantification. 9, 11 Quantitative mean and SD grayscale echo intensity measurements for both the liver and kidneys were then performed in a manner identical to that used for the PACS measurements, using an identical anatomic location on the US image and the identical ROI shape and size.
Statistical Analysis
Descriptive statistics included a demographic analysis by pathologic result, sex, and age. Patient demographics and characteristics were presented as counts and percentages. The statistical significance of differences between the 3 patient groups was assessed via v 2 tests or Fisher exact tests as appropriate.
The means and SDs of the hepatorenal ratio and heterogeneity index values from PACS measurements were calculated for each of the 3 patient groups. These means were compared by a 1-way analysis of variance, and a Tukey-Kramer adjustment was used to control the type I error rate in multiple comparisons. Receiver operating characteristic curves were formed for the hepatorenal ratio and heterogeneity index, and the area under the curve, cutoff values, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were determined. Area under the curve values closest to 1.0 represented perfect test results; values of 0.5 or less were equivalent to or worse than results than expected by random chance.
For patients classified as having hepatic steatosis, we further analyzed the hepatorenal ratio within this group to detect any possible significant differences stratified by the grade of steatosis. To do this analysis, the mean hepatorenal ratio of a group composed of patients with mild and moderate grades of steatosis (these grades were combined because the numbers were small) was compared to the mean hepatorenal ratio of patients with a severe grade of steatosis. The sensitivity and specificity of various cutoff values for the hepatorenal ratio value were compared in univariable logistic regression models predicting the severity category of hepatic steatosis. The odds ratio was calculated for the hepatorenal ratio cutoff value of 1.5.
For the 20 patients used in the validation of the PACS measurement tool, the means and SDs were Erdem Toslak et al-Quantitative US of Hepatic Steatosis in Pediatrics calculated for the echo intensity means and SDs for the liver and kidney, first for the PACS tool and then for the ImageJ application separately. The differences between ImageJ and PACS values were compared, and P values were reported from 1-sample t tests with the null hypotheses of zero difference between the measurement methods. All differences associated with P .05 were considered statistically significant.
Results
Forty-nine children who had both diagnostic focused abdominal US images and subsequent US-guided biopsy results within 3 months were included in the analysis. Among the 49 patients (mean age 6 SD, 12.8 6 4.6 years; 32 female and 17 male), 13 In the hepatic steatosis group, 15 of 17 of patients (88%) had a diagnosis of NAFLD (2 had simple steatosis; 2 had type 1 NASH; and 11 had type 2 NASH); 1 had underlying Wilson disease; and 1 had hepatitis C. In the nonsteatotic liver disease group, 5 (26.3%) had a diagnosis of primary sclerosing cholangitis; 3 had (16%) autoimmune hepatitis; 2 had nodular cirrhosis (10.5%); 2 had drug-induced acute hepatitis (10.5%); 2 had nonspecific hepatic inflammation (10.5%), and 1 each had chronic hepatitis C, a 1 -antitrypsin deficiency, chronic hepatosplenomegaly, total parenteral nutrition-related liver disease, and multifactorial liver disease.
Quantitative pathologic analyses revealed that in the group of 17 patients with hepatic steatosis, hepatic fibrosis grades were as follows: 6 (35.3%) with grade 0, 7 (41.2%) with grade 1, 2 (11.8%) with grade 2, 1 (5.9) with grade 3, and 1 (5.9%) with grade 4. When considering the degree of steatosis in this group of 17 patients, 5 (29%) had mild steatosis; 3 (18%) had moderate steatosis; and 9 (53%) had severe steatosis. Pathologic analyses showed that in the 19 patients with nonsteatotic liver disease, hepatic fibrosis grades were as follows: 8 (42.1%) with grade 0, 1 (5.3%) with grade 1, 4 (21.1%) with grade 2, 2 (10.5 %) with grade 3, and 4 (21.1%) with grade 4.
The validation analysis comparing liver and kidney grayscale echo intensity measurements obtained with the PACS tool and ImageJ software in the same 20 patients indicated no statistically significant variability between the measurement techniques (P > .05; Table 1 ).
When comparing the hepatorenal ratio as measured by the PACS tool between the 3 pathologic groups, we found that the hepatorenal ratio of the hepatic steatosis group was significantly greater than those of the control and nonsteatotic liver disease groups (P < .001; Table 2 and Figure 2) . When comparing the heterogeneity index between the groups, we found that the heterogeneity index of the hepatic steatosis group was significantly lower than that of the control group (P 5 .046; Table 2 ). Within the hepatic steatosis group, there was no statistically significant difference in the hepatorenal ratio between the mild-to-moderate steatosis group versus the severe steatosis group (P 5 .059; Table 3 ).
The receiver operating characteristic curve analysis revealed 88.2% sensitivity, 91.4% specificity, 88.3% PPV, and 94.1% NPV for the hepatorenal ratio cutoff value of 1.5 for predicting hepatic steatosis. The area under the 
Discussion
In this study, a practical PACS-based quantitative grayscale echo intensity US system was evaluated for the detection of hepatic steatosis in children. To our knowledge, this work is the largest objective US quantification study with biopsy-proven hepatic steatosis reported in the pediatric population to date. Our study results demonstrated that not only can measurements of the liver grayscale US echo intensity using the hepatorenal ratio and heterogeneity index accurately differentiate pediatric patients older than 1 year with and without hepatic steatosis, but these measurements can also be used to correctly stratify patients by the degree of severity of hepatic steatosis. Various imaging modalities, including magnetic resonance imaging, computed tomography, and US, have been used to assess patients with hepatic steatosis in a noninvasive fashion, with magnetic resonance imaging validated as the most accurate and effective method and US as the most cost-effective. 17 Although studies in children have shown that magnetic resonance imaging measurements were strongly correlated with the histologic grades of fat in liver with high sensitivity and specificity, its applicability in the pediatric population is limited because of the high cost and the requirement for sedation. 18, 19 Computed tomography, on the other hand, is not widely accepted as a method of choice because of the ionizing radiation.
Ultrasound is attractive as a readily available and easy-to-use screening tool for children at risk for hepatic steatosis, but it has its drawbacks. B-mode grayscale US for this purpose has been primarily used in a subjective, rather than objective, format. A qualitative 4-tier US severity grading system was described by Hamaguchi et al, 4 with the scale ranging from 0 to 4, based on the liver brightness, hepatorenal echo contrast, deep attenuation (echo penetration into the deep portion of the liver), and loss of periportal echoes. One of the impediments to this subjective method is accurate detection of hepatic steatosis if only a histologically moderate or severe degree of fatty accumulation (defined as 30% of the specimen) is present within liver parenchyma. For adults with a mild histologic grade of hepatic steatosis (5%-29% of the specimen), the sensitivity and specificity were reported be as low as 53.3% and 77%, respectively; therefore, the subjective US assessment was not found to be accurate when all degrees of steatosis were considered. 17 The 4-tier subjective US assessment system when applied to adults was also shown to have substantial intraobserver and interobserver variability (54.7%-67.9% and 47.0%-63.7%, respectively). 17 Moreover, it has been postulated that hepatic fibrosis from an underlying chronic liver disease may cause an increase in hepatic echogenicity, reducing the accuracy of US for hepatic steatosis. 17 In the pediatric literature, a study of 208 children with biopsy-proven fatty liver found a correlation between the subjective US steatosis score and steatosis on biopsy, even though the individual US score category Data are presented as mean 6 SD where applicable.
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failed to predict the histologic category accurately. 20 Another study with 34 biopsy-proven pediatric patients showed that all 15 children with hepatic steatosis by biopsy had positive liver US findings, but 19 children without steatosis were rated as having at least grade 1 hepatic steatosis on US, yielding a PPV and NPV of 47% and 11%. 21 None of these pediatric studies measured the interobserver reliability of this subjective technique. 20, 21 Computer-based quantification of US images in liver diseases has been studied by some investigators, with most studies conducted in adult patients. [9] [10] [11] [12] [13] Most measurement systems require specialized computer software or complicated manual measurements. In contrast, the graphic program integrated into the PACS used in our study is readily available and easy to use. It allows a practical method of measuring grayscale echo intensity values on US images as well as providing the SD as a measure of the variation of echo intensity values. 10, 13 Furthermore, it is less cumbersome and timeconsuming, as special software does not need to be installed in the US devices or PACS, nor do images need to be transferred out of the PACS. 9, 11 Prior US quantification studies have shown that measurements of the liver echo intensity can accurately differentiate steatotic from nonsteatotic livers, which is consistent with our results. Two studies in adults used a PACS tool for quantification of US images, similar to our own. 10, 13 The hepatorenal ratio, calculated by dividing the mean liver echo intensity level by the mean kidney echo intensity level in a manner identical to the hepatorenal ratio used in our study, has been found in adults to be an accurate and effective method of detecting even small degrees of steatosis. 9, 12 Because absolute echo intensity values may be changed by altering gain and the time-gain compensation control, we elected to use a ratio or index of the liver to kidney echo intensity rather than the absolute liver echo intensity value to allow comparisons between patients. A hepatorenal index was calculated in a previous pediatric study but was defined as the mean kidney echo intensity subtracted from the mean liver echo intensity, rather than a ratio.
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In this study, we determined that the optimal hepatorenal ratio cutoff value was 1.5, resulting in 88.2% sensitivity, 91.4% specificity, 88.3% PPV, and 94.1% NPV in differentiating patients with hepatic steatosis from the remaining patients regardless of the pathologic diagnosis. These findings are consistent with those from recent adult studies, one of which found that a hepatorenal ratio cutoff value of 1.27 was associated with 100% sensitivity, 54% specificity, 100% NPV, and 54% PPV, and another found that a hepatorenal ratio cutoff value of 1.49 resulted in 100% sensitivity, 91% specificity, 88% PPV, and 100% NPV. 9, 12 Shiralkar et al 10 used the same method in adults and reported 1.34 as the optimal cutoff value for the hepatorenal ratio, with 92.11% sensitivity, 85.25% specificity, and an area under the curve of 0.92, further supporting our findings. Slight differences in sensitivity, specificity, and cutoff values might be due to the use of different US systems in each study, as well as the different age groups of the study populations. Nevertheless, this information supports the idea that the hepatorenal ratio is a useful method even with the use of different equipment, but each vendor has its own cutoff value depending on the patient age group. Further studies with different age groups for each vendor would better reveal the influence of age, thus helping optimize cutoff values. The associated PPV of 88.3% and NPV of 94.1% for this objective quantitative US method were superior results compared to the subjective 4-tier US grading system, with reported PPVs ranging from 47% to 62% in previous pediatric studies. 20, 21 We further analyzed our data according to the severity of hepatic steatosis by combining the patients with mild and moderate steatosis into a single group and those with severe steatosis into another group, but we were unable to find a significant difference between the groups (P 5 .059), contrary to a study of 45 patients in the adult literature. 12 This discrepancy may have been attributable to the smaller sample size of 17 in the hepatic steatosis group in our study.
We also calculated the heterogeneity index using the formula SD divided by mean echo intensity as a measure of parenchymal grayscale echo intensity variation within the ROI. We found significantly lower heterogeneity index values in the hepatic steatosis group than in the control group, likely resulting from the influence of higher mean echo intensity values in the denominator. Although there was a trend toward higher heterogeneity index values in the nonsteatotic liver disease group compared to the hepatic steatosis group, the difference was not significant. One prior study that measured the SD of liver parenchyma from B-mode US images with standardized parameters concluded that SD values of chronically diseased liver were significantly higher than those of normal and fatty livers. 13 One explanation that may explain the discrepancy between the results of those authors and our own might be their use of the SD instead of the index used in our study. Additionally, the narrow range of heterogeneity index values in our sample may have been an obstacle in achieving meaningful results. Therefore, we conclude that although lower heterogeneity index values may suggest hepatic steatosis in pediatric patients, reliance on the heterogeneity index value alone must be undertaken with caution, as no significant difference in the heterogeneity index was found between the hepatic steatosis and nonsteatotic liver disease groups. Instead, we suggest that the heterogeneity index should be interpreted in the context of the hepatorenal ratio. Future studies with prospective data acquisition and the use of standardized time-gain compensation and gain values may enable comparison of absolute SD values between patients, thus allowing assessment of the SD independent of echo intensity values.
Ultrasound quantification of liver parenchyma in pediatric patients using an integrated PACS tool provides new insight into the evaluation of pediatric steatotic liver diseases. Future studies on the use of the hepatorenal ratio and heterogeneity index in follow-up of hepatic steatosis may be beneficial in detecting deterioration of steatosis and providing an early indication of the progression of simple steatosis to NASH and cirrhosis.
Our study was primarily limited by the retrospective approach and the small sample size. Due to the small number of patients with simple steatosis (n 5 2), we were unable to compare the hepatorenal ratio and heterogeneity index with those of patients with NASH, which has been previously studied in adults but without promising results. 20 Future studies with larger sample sizes could be beneficial to evaluate the use of this tool in this manner. We did not evaluate body mass index, weight, height, or waist circumference parameters. However, on the basis of previous results showing no significant difference in liver parenchyma echogenicity between obese and normal-weight children, these factors would have been unlikely to have influenced our results.
In conclusion, PACS-based US quantification of the grayscale liver echo intensity is a safe, accurate, and easily applicable objective method for the diagnosis of hepatic steatosis in children older than 1 year. A hepatorenal ratio of greater than 1.5 can be used as a conservative parameter, permitting increased confidence in discriminating hepatic steatosis from other conditions. This method may aid in clinical decision making regarding the need for liver biopsy and other invasive interventions in pediatrics.
